Johannes Jacob Pieter Kastelein, Chief Scientific Officer at NewAmsterdam Pharma, sold NAMS on Sep 30, 2026
Data as of Oct 16
▼ SELL$1.3M50,246 shares at $25.03Johannes Jacob Pieter Kastelein Chief Scientific OfficerNAMS NewAmsterdam Pharma Co N.V.
- Traded
- Sep 30, 2026
- Disclosed
- Oct 2, 2026
- Filed
- 2 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
NAMS since disclosure
−14.5%
after the sale
Similar stocks (XLV) since disclosure
+6.3%
XLV — its sector index fund
Change in closing price from Oct 2, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.